Luke Halpern, Assistant Editor

Sundar Jagannath, MD, MBBS, explains how linvoseltamab showed strong efficacy and tolerability in the LINKER-MM1 trial, making it an appealing option for older patients with relapsed or refractory multiple myeloma (MM).

High levels of remnant cholesterol were associated with increased risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD) independent of low-density lipoprotein cholesterol (LDL-C).

The approval represents a major advancement for patients with moderate-to-severe chronic hand eczema, as delgocitinib becomes the first treatment available for this population in the US.

Immense burden is laid upon patients with cancer who are infected with COVID-19, as they are at higher risk of experiencing cancer treatment disruptions and severe illness that necessitates hospitalization.

Adam James, PharmD, and Chris Altman, PharmD, explain how pharmacists can build trust and reduce vaccine hesitancy by clearly communicating thimerosal’s limited role in today’s immunizations and addressing patient concerns with empathy and education.

Pharmacists are pivotal in optimizing GLP-1 receptor agonist therapy.

Debra Patt, MD, PhD, MBA; and Houston Holmes, MD, explore how the removal of risk evaluation and management strategies (REMS) for chimeric antigen receptor (CAR) T-cell (CAR T) therapies can improve health equity, expand access in community settings, and elevate the pharmacist’s role in care coordination.

In the double-blind portion of Vibrance-1, alixorexton improved wakefulness while eliciting broad benefits in patient-reported outcomes.

From AI-powered prescription fulfillment to the expansion of PillPack for Medicare patients, Carey outlines how Amazon Pharmacy is streamlining access, improving affordability, and setting the stage for a more patient-centered health care future.

Challenges faced by individuals living with HIV include weight gain, cardiovascular risks, and healthy aging strategies.

Education initiatives, facilitation, and immunization on the part of pharmacists were found to significantly increase uptake of pneumococcal vaccines among older adults.

Researchers unveil a groundbreaking method using polypurine hairpins to inhibit PCSK9, offering a promising alternative for lowering cholesterol and reducing cardiovascular risk.

A large retrospective study funded by the CDC indicates broad additional protection against COVID-19, especially for older adults and immunocompromised patients.

Statins such as simvastatin do not have additional antidepressive effects in combination with standard escitalopram treatment in patients with comorbid major depressive disorder (MDD) and obesity.

Receiving a COVID-19 vaccination vastly reduced the risk of long-term hospitalization, necessitating dialysis, and morbidity in patients hospitalized with acute kidney injury related to SARS-CoV-2 infection.

Adam James, PharmD, and Chris Altman, PharmD, discuss renewed public scrutiny of thimerosal, its limited use in vaccines today, and how new guidance may affect pharmacists and patient confidence moving forward.

Millions of seniors and Medicare beneficiaries managing chronic conditions have new options for medication delivery and adherence support.

The fibroblast growth factor receptor 2b (FGFR2b)-inhibiting bemarituzumab demonstrated improvements in overall survival and other key secondary end points compared with placebo in first-line gastric cancer.

Debra Patt, MD, PhD, MBA; and Houston Holmes, MD, discuss the ramifications of the FDA's removal of REMS requirements for approved chimeric antigen receptor (CAR) T-cell (CAR T) therapies.

Patients with inflammatory rheumatic diseases may have a protective effect against serious COVID-19 outcomes once they receive a pneumococcal vaccination.

Previously indicated to reduce the risk of end-stage kidney disease, cardiovascular death, and hospitalization for heart failure (HF) in chronic kidney disease, finerenone is now approved for patients with HF directly, offering a new treatment option.

Complete response letters, which indicate reasons why a drug could not be approved in its current form, offer insightful information to drug developers on the inner mechanisms of the FDA’s approval process.

Gustavo Alva, MD, a board-certified psychiatrist, discusses the importance of mental health awareness among pharmacists and patients.

By closing the gap on patients who are recommended lipid-lowering therapies but do not receive them, researchers say that thousands of cardiovascular events could be prevented and billions of dollars would be saved.

mRNA-1273, marketed as Spikevax by Moderna, is now fully approved for individuals aged 6 months through 64 years with high-risk features for severe COVID-19.

In a community of older adults, initiating a pneumococcal vaccination support program reduced annual pneumonia-related mortality by 25%, demonstrating broad public and individual health benefits.

The lawsuit alleges that Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. violated the law when issuing new guidance for COVID-19 vaccination.

Experts discussed the promising future of pericarditis treatment.

The new formulation contains little IgA, reducing possible risks associated with infusion in patients with primary immunodeficiency.

Sunvozertinib becomes the first and only targeted approval treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations.